Chinese scholars have found that Chinese herbal extracts can inhibit brain cancer

Hu Yi has published 30 papers in International English journals and domestic professional journals, both of which are influential Hu Yi, a neurosurgeon at Shengjing Hospital Affiliated to China Medical University, is treating patients Liaoning News, China news, June 2 (Zhao Guihua) on June 2, the reporter learned an exciting good news from the health system of Liaoning Province Hu Yi, a neurosurgeon scholar of Shengjing Hospital Affiliated to China Medical University, made great progress in clarifying the inhibitory effect and mechanism of dihydroartemisinin (DHA), a traditional Chinese herbal medicine extract, on brain malignant glioblastoma, in order to To traditional Chinese herbal medicine treatment of glioblastoma provides a theoretical basis That is to say, the research results will bring new ideas and directions for glioblastoma, a disease that is hard to cure, and more brain tumor patients will benefit in the future Brain glioblastoma, commonly known as "brain cancer", is the most common and serious brain cancer In recent years, the incidence of glioblastoma shows a trend of younger and more serious The initial symptoms of the disease are not obvious, so early diagnosis is very difficult, many patients found that it was late The treatment of brain malignant glioblastoma is extremely difficult, and the effect of drug chemotherapy is not good DHA is an extract derivative of traditional Chinese herbal medicine Artemisia annua, which is traditionally used to treat inflammatory diseases such as malaria Hu Yi's research team has been working on the application of artemisinin and its derivatives in the treatment of brain cancer since 2009 The latest research of Hu Yi's research team found that DHA can significantly inhibit the activity of glioblastoma cells and play an anti-tumor role by increasing the production of active oxygen substances in tumor cells and activating p53 gene Hu Yi introduced to reporters that ROS in cells can inhibit tumor growth P53 gene is a kind of tumor suppressor gene, which can inhibit the formation and development of tumor In a variety of malignant tumors, including glioblastoma, the activity of p53 gene is inhibited, which provides an opportunity for the development of malignant tumors It is exciting that the team of Hu Yi found that DHA can effectively improve the level of ROS production in glioblastoma cells and activate the p53 gene expression activity of tumor cells, so as to play an effective role in killing glioblastoma EGFR / beta catenin signaling pathway plays a role in the inhibition of tumor by DHA This signaling pathway is closely related to the occurrence and development of many kinds of malignant tumors DHA can play the above-mentioned anti-tumor role by inhibiting this signaling pathway It is this similar mechanism that ensures that DHA can effectively play the role of killing glioblastoma So what is the significance of the research results for the treatment of brain cancer? Hu Yi told reporters that the current treatment of glioblastoma is still limited, mainly surgery and adjuvant radiotherapy and chemotherapy However, the disease is resistant to radiotherapy and chemotherapy At the same time, the current chemotherapy drugs may cause serious toxic side effects At present, the world is looking for more effective and safer treatment DHA and other Chinese herbal extracts have the characteristics of high therapeutic efficiency and good safety, which is a new hope for the application of traditional Chinese medicine in the treatment of malignant tumors The research results can provide experimental theoretical basis for promoting the treatment of brain cancer with traditional Chinese herbal medicine, and bring new inspiration for conquering "brain cancer", a disease that is difficult to cure, and more brain tumor patients will benefit in the future Hu Yi also said that at present, the research of DHA and other traditional Chinese herbal medicines in the treatment of brain tumors has just made progress, and there are still many research works to be completed before the clinical application in the future The research in this field has bright prospects, opportunities and challenges The research results of Hu Yi's team were published in the international famous academic journal pharmaceutical research (end) link: Hu Yi's resume, Hu Yi, male Associate Professor, associate chief physician, graduate supervisor Worked in neurosurgery of Shengjing Hospital Affiliated to China Medical University He is a young member of gliomas Committee of Chinese Medical Association, a member of Chinese society of neuroscience, a member of Neurosurgery Branch of Chinese Medical Association, and a neurosurgeon specialist of Chinese Medical Association He graduated from the Japanese class of clinical medicine major of China Medical University in 2003, and was admitted as a neurosurgery graduate student in the same year In 2005, he went to the neurosurgery teaching and Research Office of Akita University in Japan to study After graduation, he remained in neurosurgery of Shengjing Hospital Affiliated to China Medical University and obtained a doctor's degree Engaged in neurosurgery clinical, scientific research and teaching for many years, master the diagnosis and treatment of Neurosurgery diseases It has a deep research on the diagnosis and comprehensive treatment of intracranial malignant tumors such as gliomas, the anatomical characteristics of the skull base, and the functions of cranial nerves It is good at the surgical treatment of skull base tumors such as craniocerebral trauma, cerebral hemorrhage, hydrocephalus, pituitary tumor, meningioma, craniopharyngioma, etc Its specialty and research direction are minimally invasive surgical treatment via navigation, neuroelectrophysiological detection of cranial nerves and brain functional areas, and neuroendoscopy Minimally invasive surgery To understand the latest development of Neurosurgery at home and abroad, to participate in the scientific research on the pathogenesis and gene therapy of brain gliomas, and to undertake two scientific research projects funded by the National Natural Science Foundation, one of which is the first person in charge He has published 30 papers in International English journals and domestic professional journals, including 16 first authors Publish a professional translation As a reviewer of PLoS One, Journal of stroke and cerebrobascular, molecular and cellular biology, Frontiers in neurology, clinical neurology and Neurosurgery, Chinese Journal of neuropsychiatric diseases, Chinese Journal of cell biology and many other professional academic journals at home and abroad, as well as e-journal of translational medicine, translational Editorial board of professional journals such as neuro oncology and metabolic brain disease,